On April 4, 2024 Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, reported that it will present the results of preclinical data of HH018-sesutecan, a tumor microenvironment targeting CD98-directed ADC, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (Press release, Huahui Health, APR 4, 2024, View Source [SID1234641809]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) meeting will be held April 5–10, 2024, in San Diego, California.
Topic: A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 4
Session Date and Time: Wednesday Apr 10, 2024 9:00 AM – 12:30 PM
Location: Poster Section 54
Poster Board Number: 1
Abstract Presentation Number: LB425
Presenter: Bin Chen, CEO of Huahui Health. Zhu Chen, CSO of ProfoundBio